Nature Communications (Nov 2016)
Control of diabetic hyperglycaemia and insulin resistance through TSC22D4
- Bilgen Ekim Üstünel,
- Kilian Friedrich,
- Adriano Maida,
- Xiaoyue Wang,
- Anja Krones-Herzig,
- Oksana Seibert,
- Anke Sommerfeld,
- Allan Jones,
- Tjeerd P. Sijmonsma,
- Carsten Sticht,
- Norbert Gretz,
- Thomas Fleming,
- Peter P. Nawroth,
- Wolfgang Stremmel,
- Adam J. Rose,
- Mauricio Berriel-Diaz,
- Matthias Blüher,
- Stephan Herzig
Affiliations
- Bilgen Ekim Üstünel
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Kilian Friedrich
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Adriano Maida
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Xiaoyue Wang
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Anja Krones-Herzig
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Oksana Seibert
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Anke Sommerfeld
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Allan Jones
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Tjeerd P. Sijmonsma
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Carsten Sticht
- Center for Clinical Research, Medical Faculty Mannheim
- Norbert Gretz
- Center for Clinical Research, Medical Faculty Mannheim
- Thomas Fleming
- Department of Medicine I and Clinical Chemistry, Heidelberg University
- Peter P. Nawroth
- Department of Medicine I and Clinical Chemistry, Heidelberg University
- Wolfgang Stremmel
- Department of Internal Medicine IV, Heidelberg University Hospital
- Adam J. Rose
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Mauricio Berriel-Diaz
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- Matthias Blüher
- Department of Medicine, University of Leipzig
- Stephan Herzig
- Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, and Joint Heidelberg-IDC Translational Diabetes Program
- DOI
- https://doi.org/10.1038/ncomms13267
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 11
Abstract
TSC22D4 regulates hepatic lipoprotein production, but has so far mainly been studied in the context of cancer cachexia. Here, the authors show TSC22D4 inhibition improves insulin sensitivity in several mouse models of diabetes, which they attribute at least in part to the induction of secreted LCN13.
